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Regenerative medicine therapy is inspired by current research advances in cellular biology, 
genetic engineering, synthetic biology, material sciences and so far contributes to the  tradi-
tional therapy, making  resistant diseases curable. Nowadays, chronic wound healing is pos-
sible due to cell-based regenerative technologies and recent non-cell therapeutic approaches. 
Here we review clinical applications of human stem cells, as well as cellular and tissue prod-
ucts as alternatives to the traditional therapy of non-healing wounds. The cell-based technolo-
gies for tissue regeneration and bioengineering utilize stem cells that are either injected into 
bloodstream or positioned directly into the target area. Cell-free regeneration technologies 
require either stem cell products, i.e., secretomes or their separate components, extracellular 
membrane vesicles, or tissue products. The stem cell therapies are designed to replace criti-
cally absent components of wounded or degenerative tissue. The stem cell secretome can 
promote the repair of damaged tissues independently of parent cells. Extracellular membrane 
vesicles mimic and recapitulate the mechanisms of stem cells in tissue regeneration and there-
fore might be promising for chronic wound and severe burns healing. The tissue products 
traditionally remain efficient wound healing remedies along with emerging advanced tech-
nologies.
K e y w o r d s: wound healing, cell and cell-free technologies, stem cells, secretomes, extracel-
lular membrane vesicles, tissue products
Introduction
The skin is a protective barrier of the body 
systems against harmful environmental factors, 
and its damage can result in either temporary 
or full disability, sometimes followed by lethal 
outcome. The process of cutaneous wound 
healing represents a cascade of overlapping 
molecular and cellular events that are well-
regulated by a complex highly interconnected 
and multifaceted system. The impairment or 
loss of regeneration system components leads 
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to delay in tissue regeneration. Chronic wounds 
have lower levels of growth factors and che-
mokine production, a slower vessel formation, 
fibroblast proliferation, the interrupted inflam-
mation in a tissue reparation process [1]. If 
traditional conservative and surgical therapies 
do not aid at curing chronic wounds, the latter 
accepted as non-healing. The non-healing 
wounds are often either in the state of cellular 
aging or lack of resident Stem Cells (SC), or 
other cells needed for a healing progress [2, 
3]. The tissue regeneration efficiency is com-
plicated by various factors, such as aging, 
stress, diabetes, obesity, alcohol consump-
tion etc. The impaired skin healing represents 
a burden for both patients and the healthcare 
system and creates a social-economic problem. 
In the developed countries, 1.0–2.5 % of pop-
ulation suffer from incurable wounds [4]. 
Chronic wounds, especially venous and arte-
rial ulcers, are called a ‘silent epidemy’. In 
recent years, tremendous progress has been 
made in delineating the factors and mecha-
nisms involved in a tissue repair, and this aca-
demic knowledge has provided a basement for 
advanced wound healing. The contemporary 
cell and cell-free tissue regeneration technolo-
gies are in use to overcome the limitations of 
traditional medicine (Fig. 1).
The cell-based regeneration therapy in-
volves two fundamental components: stem 
cells and bioengineered scaffolds. Stem cells 
are the significant players in the formation of 
the de novo tissue, whereas scaffolds serve to 
mimic extracellular matrix and support 
SCs [5]. Another approach is based on the 
cell-free regeneration technologies, involving 
the use of products generated by SCs — full 
secretomes — [6] or their separate compo-
nents, extracellular membrane vesicles 
(EMVs) [7], as well as EMVs of other cell 
types [8]. Gene therapy also belongs to the 
regenerative advanced therapy, however, it is 
not in the focus of this review. The tissue 
products, such as extracts remain efficient 
wound healing remedies along with advanced 
technologies.
Cell therapy for the treatment of chronic 
wounds
In this review, we are paying attention to a 
vital role of SCs in the maintaining of adult 
tissues and injury repair, not discussing other 
roles. Their functions are not restricted to the 
tissue regeneration, and SCs are known to take 
part in the homeostasis of damaged tissues, e.g., 
by inhibiting the formation of reactive oxygen 
forms or modulating the immune response [9, 
10]. The cell regeneration technologies are 
based, first of all, on the capacity of undiffer-
entiated SCs to differentiate into diverse lin-
Fig. 1. Cell and noncellular regeneration technologies in 
the treatment of chronic wounds.
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eages of specialized cells. Different SCs rep-
resent valuable reserves of an organism that 
can be employed, when needed, to develop into 
specialized cells, to restore healthy cells or to 
replace damaged or aging ones. 
Stem cells have been classified by their 
capability to differentiate into various types of 
cells (by potency) and by their origin [11]. 
Totipotent cells (first cells from a zygote divi-
sion) differentiate into all possible types of 
cells and organs. Pluripotent cells also have 
unlimited capacity to differentiate and give rise 
to almost all cell lineages derived from meso-
derm, endoderm and ectoderm (germ layers). 
Multipotent cells are capable of differentiation 
into several types of closely related cells such 
as hematopoietic SCs that can become red and 
white blood cells or platelets. Another example 
is Mesenchymal/stromal Stem Cells (MSCs) 
from the bone marrow stroma and other tis-
sues, which can differentiate into various cell 
lineages, including classical mesodermal 
ones ― bone, cartilage and fat. Olygopotent 
cells differentiate into a limited variety of cell 
lineages, e.g., into lymphoid or myeloid stem 
cells. Unipotent cells are able to regenerate 
only the cells of their own type.
There are four main types of stem cells 
classified by origin: embryonic stem cells 
(ESCs), adult organism SCs, fetal SCs (from 
the fetal part of a placental complex — cho-
rion, amnion, placental villi — and the um-
bilical cord) and induced pluripotent stem cells 
(iPSCs). ESCs originate from the blastocyst, 
an early stage of embryonic development, and 
have the highest potential for differentiation. 
However, there are ethical issues associated 
with the production of ESCs that restrict their 
use. The adult SCs  (also referred to as so-
matic or tissue specific stem cells) are more 
specialized than embryonic stem cells and 
serve in the body for the regeneration of aging 
or injured tissue. The progress in SCs research 
led to the emerge of a new SCs type, called 
iPSCs, when the adult stem or progenitor cells 
were reprogrammed to an embryonic stem 
cell-like state by introducing genes responsible 
for growth factors important for maintaining 
the essential properties of ESCs [12]. These 
reprogrammed adult cells create a new power-
ful way to “de-differentiate” cells and use 
iPSCs in regenerative medicine, as well as a 
new tool for drug development and disease 
modelling. Fetal stem cells have the advantage 
over adult SCs due to a younger age and there-
fore fewer acquired mutations. Phenotypically, 
placental MSCs are similar to MSCs of the 
bone marrow and the fat tissue, however, this 
cell lineage possesses a higher capacity to dif-
ferentiate into other cell lineages — myo-
genic, angiogenic, pancreatic, cardiogenic, 
neurogenic etc. as compared to adult SCs [13].
Progenitors of the specialized cells are ear-
ly descendants of SCs that can differentiate, 
generally giving rise to a single cell lineage, 
but they cannot divide and proliferate unlimi-
tedly, i.e., they are more limited than the SCs 
in terms of division and differentiation. 
Progenitors act as the element of a tissue rep-
aration system, and these cells are used by an 
adult organism to replenish specialized cells 
in blood, skin and intestine tissues. Most pro-
genitor cells remain quiescent and can be ac-
tivated, if the tissue is either damaged or ag-
ing [14]. 
The undifferentiated cells were found in the 
nineteenth century, however, their existence 
was proved not long ago, in the 1960s. During 
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the last two decades, exogenous SCs were 
administered in regenerative medicine to treat 
degenerative tissues and traumas with limited 
regenerative capacities. Therapeutic potential 
of SCs has three main mechanisms of action: 
(a) self-guidance, or the ability to migrate into 
the damaged area, following chemical gradi-
ents; (b) differentiation into various lineages 
of cells, which leads to a renewed functional-
ity of damaged tissues; (c) a secretion of bio-
active factors that can potentially impact both 
local and systemic physiological processes [11] 
(Fig. 2). 
MSCs are some of the usable cells in rege-
ne rative medicine and tissue bioengineering 
due to their advantages, such as immunocom-
patibility, proliferation and multipotency. 
Initially, in regenerative medicine, the adapted 
hematopoietic MSCs were used for the repla-
cing of lost cells occurred during specific di-
seases or traumatic events. At the end of the 
last century, adult SCs were considered to be 
more promising because they have much wid-
er developmental potential in situ and can be 
relatively easy and abundantly obtained from 
different tissues of humans or animals, such 
as the bone marrow or the fat tissue. Presently, 
the most common source of MSCs is the bone 
marrow, however, harvesting and processing 
of the bone marrow MSCs have major draw-
backs and limitations [15]. The fat tissue-de-
rived mesenchymal stem cells (adipose MSCs) 
are multipotent stem cells that can differentiate 
into various cell types and, most importantly, 
can be harvested from own fat tissue abun-
dantly. Adipose MSCs play a key role in re-
constructive or tissue engineering medi-
cine [16]. Currently, the iPSCs offer a promis-
ing strategy to generate patient-specific SCs 
lines [17]. Substantially, the iPS cell techno-
logy is a hallmark in regenerative medicine 
and revolutionizes the medical field. However, 
the technical challenges must be overcome 
before this strategy can be deployed in trans-
lational regenerative medicine; there are also 
open questions remaining, e.g., regarding the 
potential tumorigenicity of the iPSC-derived 
cells or the impact of epigenetic background. 
Fig. 2. Bioeffects of stem and pro-
genitor cells in wound healing. Epi-
dermal, dermal cells and cells of hair 
follicles, as well as circulating in the 
bloodstream bone marrow mesenchy-
mal stem cells, migrate to the dam-
aged skin and take part in its regener-
ation [21]. Stem cell therapeutic effi-
cacy in cutaneous wound healing is 
associated with the ability to migrate 
into the damaged area, following 
chemical gradients (a); differentiation 
into various lineages of cells, which 
leads to a renewed functionality of 
damaged tissues (b); a secretion of 
paracrine factors (c) [11]. 
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The emerging regenerative therapies, based on 
fetal SCs, show their high potential for clinical 
applications [18].
For the cell and tissue regeneration, undif-
ferentiated SCs are collected from the patient’s 
body or from donor material. Cell therapy can 
be autologous, when own cells are used, or 
donor SCs are used for the аllogeneic trans-
plantations. Although MSCs are present in 
multiple tissues, their overall quantity in the 
body is scarce. Therefore, cell expansion in 
vitro is needed before administration. 
According to the criteria of the International 
Cell Therapy Society, SCs are considered us-
able for regenerative medicine, if (a) produce 
enough cells (lg6-lg9 CFU/mL) in vitro; 
(b) differentiate into several lineages of cells; 
(c) can be taken out by minimally invasive 
procedures; (d) must express Clusters of 
Differentiation (CD) 73, 90 and 105, and 
(e) attach to plastic surfaces during the cultu-
ring process (see more in [19]). Importantly, 
MSCs can be obtained from the patient through 
a rather cheap procedure (from the fat tissue) 
and even a non-invasive one (from urine). The 
stem cells treatment can be based on both their 
intravenous injection similarly to drugs and 
the local use in the target tissue. The cell ther-
apy is successful in the treatment of many 
diseases, as well as in healing chronic wound 
of various etiologies.
Stem cells in the treatment of cutaneous 
wounds
Various methods and drugs for the treatment 
of wounds are strictly oriented on the stage of 
the wound process, which does not depend on 
the mechanism of the wound formation and 
occurs according to a universal scheme, unify-
ing 4 overlapping phases: hemostasis, inflam-
mation, proliferation and remodelling (well 
reviewed in [20]). For a better understanding 
of the SCs role (and their secreted components, 
as well) in wound healing, here we represent 
a short description of successive events in tis-
sue regeneration under this process (Fig. 3). 
The hemostasis phase proceeds due to fibrin 
and platelets, which trigger a cascade of blood 
coagulation in normal lesion healing. The for-
mation of the platelet plug and fibrin matrix 
leads to the release of cytokines and growth 
factors, which elicit an inflammatory reaction 
that is necessary to progress the tissue re-
pair. Fibrin derived from thrombocytic fibrin-
ogen acts as a matrix for macrophages and 
fibroblasts that appear in the lesion site. The 
inflammation phase begins once the neutro-
phils are attached to the endothelium within a 
few minutes of the injury. Neutrophils use 
elastase and collagenase to facilitate migration 
in the extracellular space, where they capture 
bacteria, degrade the matrix proteins and at-
tract additional neutrophils and macrophages. 
Macrophages are perhaps the most important 
of inflammatory cells in acute healing as they 
destroy pathogenic microorganisms, degrade 
damaged tissue in the wound and stimulate the 
formation of granulation tissue and blood ves-
sels via growth factors such as platelet derived 
growth factor, transforming growth factor beta 
(TGF-β), fibroblast growth factor and proin-
flammatory cytokines: interleukin-1 beta (IL-
1β), interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNF-a). Therefore, a deficiency 
of neutrophils and macrophage cells is respon-
sible for the inhibition of the inflammatory 
response phase and the healing process stagna-
tion. Also, the excessive release of IL-6 and 
176
I. V. Orlovska, A. H. Haidak, N. O. Kozyrovska
IL-1β from neutrophils and macrophages leads 
to the formation of chronic wounds. 
Lymphocytes are the last to fall into the wound 
and play an important role in the production 
of interleukin-2, which in turn plays a role in 
attracting fibroblasts. The participation of fi-
broblasts begins with the production of matrix 
metalloproteinases that facilitate the movement 
of fibroblasts in the matrix. However, in chron-
ic wounds, elevated metalloproteinases have 
been shown to degrade the extracellular matrix 
(ECM). Chronic wounds often remain in a 
prolonged inflammatory phase and lack the 
capability to transition into the subsequent 
phases to complete the wound healing process, 
resulting in an open wound. The proliferation 
phase encompasses fibroplasia, granulation, 
epithelization, angiogenesis and proceeds with-
in 24 hours after the formation of the lesion. 
The newly formed fibrin matrix allows kera-
tinocytes to migrate from the edge of the 
wound and from the follicles of the hair to 
wound bed. By decreasing the proteolytic ac-
tivity of metaloproteinases, fibroblasts begin 
Fig. 3. A schematic course of healing in normal and chronic wounds [20]. 
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to produce structural proteins such as collagen, 
elastin and extracellular matrix proteins, i.e., 
fibroblasts are important for the proliferation 
of the dermal matrix. This stage is regulated 
by two growth factors: TGF-β, secreted by 
platelets and macrophages, as well as connec-
tive tissue growth factor, which is secreted by 
the fibroblasts. As a result, epithelization oc-
curs by the propagation and migration of epi-
thelial cells under assistance of both epithelial 
and keratinocytes growth factors, as well as 
other factors. At the same time, the vascular 
endothelial growth factor promotes angiogen-
esis. Remodelling phase is a part of the wound 
healing completion. The granulation tissue is 
gradually remodelled, forming scar tissue. The 
contraction of the wound begins due to phe-
notypic changes in fibroblasts and their trans-
formation into myofibroblasts. Metallo prote-
ina ses and their tissue inhibitors reorganize 
type III collagen fibers into a more potent 
collagen type I network. The process of re-
modelling takes weeks to several years.
The lesion healing progression depends on 
a well-coordinated interplay of cell-signalling 
events at the wound site and surrounding tis-
sues, in which endogenous SCs are vital play-
ers. In case of skin tissues damage, SCs from 
several locations are mobilized via the periph-
eral bloodstream to the injured site for differ-
entiation into specific progenitor cells, which 
in turn differentiate into specialized cell types 
necessary for tissue regeneration. Epidermal, 
dermal cells and cells of hair follicles, as well 
as circulating in the bloodstream bone marrow 
MSCs, can migrate to the damaged skin and 
take part in its regeneration [21]. 
For chronic wound healing, populations of 
SCs from epidermis, dermis and hair follicles 
are not easy to isolate and support, so MSCs 
of the fat tissue, the bone marrow and pla-
centa are in use to replace skin SCs. MSCs 
source selection is based on the kind of wound, 
a patient’s age and condition. One of the first 
successful treatments of chronic non-healing 
wound was performed with the bone marrow-
derived MSCs [22]. The wound, which previ-
ously failed to heal with both bioengineered 
skin and autologous skin transplants for more 
than 1 year, has been closed after the applica-
tion of MSCs. There were previously unseen 
signs of curing in the wound such as an in-
crease in reticulin fibres and in overall vascular-
ity. During the last ten years, it has been prov-
en that the adipose MSCs had a favorable effect 
on wound healing through inflammation inhibi-
tion, an induction of angiogenesis, a prolifera-
tion of fibroblasts and keratinocytes, a recon-
struction of extracellular matrix [23]. In the 
treating of complex wounds, such as diabetic 
ulcers, it is important to promote the process 
of blood vessel regeneration. That is overcome 
by the iPSCs potential, which can efficiently 
influence the revascularization of wound bed 
[24]. Proangiogenic endothelial progenitor cells 
have also been shown to improve healing in 
cutaneous wounds by enhancing the neovascu-
larization of granulation tissue in vivo [25]. 
Placental MSCs have a potential for the treat-
ment of chronic wounds, since they have a 
number of advantages over other stem cells: 
(a) possess more pronounced immunomodulat-
ing effect and (b) higher proliferation rates; 
(c) demonstrate lower immunogenicity; (d) can 
differentiate into various cell linea ges [19, 26]. 
Taken together, all these studies show that 
human SCs play a vital role in damaged tissue 
regeneration and are used in curing different 
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types of wounds, increasing the rate of healing 
and reducing scarring. The evidence suggested 
that the healing effects were largely due to the 
inflammation regulation by factors released, 
stimulation of new vessel and granulation tis-
sue formation, guidance of the epithelial kera-
tinocytes and fibroblasts, improved dermal 
matrix deposition. 
Currently, there are a few finished clinical 
trials of SCs in the treatment of wounds, ulcers 
and burns. For example, the successful treat-
ment of diabetic foot ulcer using the placental 
MSCs, incorporated in a sodium alginate hy-
drogel, has been achieved recently [26]. The 
progress in the clinical trials of novel MSC-
based technologies can be followed at the 
National Institute of Health web-site www.
clinicaltrials.gov.
A delivery of stem cells
Systemic administration of SCs is limited by 
the difficulties of tissue targeting. In some 
cases, delivery via the circulatory system could 
be harmful and lead to toxic effects. Inefficient 
delivery of SCs to the targets followed by low 
cell levels or their weak differentiation and 
engrafting causes problems in treatments. 
Therefore, for many cutaneous wounds curing, 
the regeneration therapies are delivered to the 
specific site of tissue repair. 
The challenge of successful ex vivo expan-
sion of SCs is that the cells need to proliferate 
and preserve their stem cell properties. It pro-
motes researchers to elaborate new approach-
es to deliver SCs or progenitor cells into 
wound bed and bioengineering neo-tissues. For 
wound healing, SCs are delivered preferen-
tially inside a three-dimentional (3D) architec-
tural constructs resemble to a skin. In vivo, the 
SC microenvironments (niches) are multi-di-
mensional, multi-factorial systems that regu-
late the quiescence, proliferation, activation of 
SCs and play an essential role in the differen-
tiation process [27]. This known fact is applied 
in bioengineering to modulate more favorable 
conditions for the SCs within a 3D than 2D 
matrix. Bioengineered scaffolds that can also 
be enriched with bioactive molecules such as 
cytokines, growth factors etc. should support 
cells by mimicking the function of a native 
ECM. The effectiveness and efficiency of bio-
mimicking materials are dependent on several 
factors, such as the choice of material, the cell 
type, the physio-spatial properties within the 
construct and so on. Different 3D systems such 
as cell-encapsulating hydrogels and other po-
rous biomimetic scaffolds are discussed 
in [28]. In this background, current research is 
focused on the developing of an artificial skin 
that could fully imitate a natural skin architec-
ture and its functionality needed for the SCs 
transplantation. The cell-free biomaterials, e.g., 
a pig skin, amniotic membrane etc., were used 
to create a 3D-template optimal for SCs growth 
and differentiation [29]. Another approach is 
encapsulating SCs in hydrogels, which pro-
vides a true 3D system that supports several 
SC properties. Hydrogels can be made from 
natural or synthetic polymers [30]. The natural 
materials used for hydrogel synthesis include 
collagen, hyaluronic acid (HA), alginate, chi-
tosan, bacterial cellulose. The latter is a bio-
degradable porous scaffold sponge-like 3D 
material that serves for cell attachment and 
supports their growth. For the in vitro expan-
sion of the SCs, several experiments have been 
performed using cellulose, e.g., within com-
posites of cellulose and HA or gelatin, the 
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dental pulp MSCs were grafted and well dis-
tributed [31]. A combination of SCs with the 
highly biocompatible and clinically relevant 
bacterial cellulose renders new possibilities 
and potential in clinical applications of 3D 
scaffold systems. For better mimicking, bio-
polymer scaffolds are functionalized by need-
ed biomolecules. For example, to recapitulate 
the adhesive properties of the ECM, the hy-
drogel was equipped with short RGD (the 
tri-amino acid sequence, arginine-glycine-
aspartate)-peptides, to which cells can adhere 
via integrin receptors [32]. Currently, the re-
generative cell technologies also employ syn-
thetic polymers, including polyvinyl alcohol, 
polycaprolactone etc., as a niche for SCs to 
improve their survival and paracrine activity 
required for a better wound healing [33]. 
Scaffold-based SC delivery is becoming 
increasingly popular. It does not only provide 
wound dressing, but also protects SCs and 
significantly accelerates wound healing, com-
pared to injection techniques, both in animal 
models of wound healing and clinical set-
tings [33, 34]. Meanwhile, a 3D- printing is a 
potential solution to fabricate skin constructs 
using biomaterial scaffolds with stem cells. 
The 3D-printing is a method based on the 
digital data of a 3D-structure to be converted 
into the real objects. In contrast to applications 
of solvents or molds, the 3D-fabrication en-
ables to create the data on digital platform. 
Bioprinting is applied to develop skin equiva-
lents for wound healing therapy [35].
Along with the elaboration of efficient MSC 
delivery methods, researchers develop the 
strategies for producing stem cells of the next 
generation with improved regenerative ca-
pacities [36]. Using the genetically modified 
MSCs, capable to secrete novel bioactive mol-
ecules, e.g., the growth factors, contributes to 
both higher local MSCs concentrations and 
potentiating novel bioeffects in the target 
area [37]. The emerging technologies of ge-
nome editing, especially, transcription activa-
tor-like effector nucleases or clustered regu-
larly interspaced short palindromic repeats 
(CRISPR)-associated protein-9 nucleases 
(Cas9), have provided robust tools for bio-
medical research [38–41]. The generation of 
iPSC from patients with inherited disorders 
and subsequent genomic correction of the 
disease-causing mutations could provide an 
ideal therapeutic approach. The next challenge 
is to utilize these studies for the generating of 
full complex organs as a complete cell therapy 
and bioengineering. However, there is a grow-
ing concern about the ethical aspect of the SCs 
gene editing. At the same time, the technology 
of genome editing may safely serve in the area 
of wound healing, e.g., researchers have re-
cently reported engineering MSCs that over-
express platelet-derived growth factor B with 
improved wound healing capacity [42]. 
CRISPR-Cas9 technology was also used to 
eradicate the functions of porcine endogenous 
retroviruses, targeting the porcine genome, in 
the cells used for making the donor graft [43].
Genetically modified MSCs are promising 
agents for current and future regenerative 
medicine, however, even a simple preliminary 
treatment of MSCs with chemical, physical or 
biological factors improves the cell survival 
and activity [44]. 
Limitation of stem cell therapy
MSC-based therapy is capable of what the 
traditional therapy cannot accomplish: it pro-
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vides missing cells for regeneration of tissues 
and organs. This novel approach in regenera-
tive medicine is especially indispensable in 
relation to aging and age-related diseases. At 
the same time, MSC therapy makes some con-
cerning challenges, including the genetic in-
stability of MSCs, immune-related rejection 
and poor engraftment, limited survival rate, 
etc. All signalling pathways remain unknown 
yet. Besides, the tumor formation is a major 
concern of MSC therapy in clinical applica-
tions. There are some limitations in the MSC 
isolation, large-scale production, storage and 
distribution. However, these major drawbacks 
and limitations depend on the depth of current 
research and technical challenges.
Cell-free technologies: secretomes 
of stem and other cell types
In the 1990s, the evidence appeared that SCs 
carried out their functions via paracrine effects 
[45]. The non-cellular therapy concept was 
born, and in this light, MSC secretomes (MSC-
sec) can be considered as a valuable source of 
therapeutic agents, such as growth factors, 
cytokines etc. that can be therefore used for 
regenerative medicine purposes. Accordingly, 
the interest to the full MSC-secs as a healing 
remedy is growing. Secretome denotes all 
secreted organic molecules, as well as organic 
and inorganic substances, by biological cells, 
tissues, organs and organisms. Secreted factors 
(soluble proteins, e.g., cytokines, chemokines, 
growth factors, as well as lipids, nucleic acids 
and EMVs) [46] can change the order of cell 
division, differentiation, apoptosis, immune 
status and affect other processes. Various SCs 
differ in secretion of bioactive cell compo-
nents; the variations in MSC-sec also depend 
on the extrinsic cues [47]. Two main groups 
of secretome components — the set of bioac-
tive molecules and EMVs — can trigger the 
regeneration and repair to some extent by 
themselves, independently, and may allow an 
increased cell proliferation, differentiation, 
angiogenesis and neurogenesis, as well as a 
reduction in inflammatory responses. Overall, 
this can lead to the improvements in tissue 
regeneration and the rates of healing, including 
wound healing, successfully proven in pre-
clinical studies [47–51]. Recent preclinical in 
vitro study has demonstrated that the MSC-sec 
activated the Phospho-Inositide 3-Kinase 
(PI3K)/Akt [52] or Focal Adhesion Kinase 
(FAK)/extracellular signal-regulated kinase 
(ERK)1/2 [53] signalling cascades. The first 
pathway is known to play central regulatory 
roles in MSC survival, proliferation, migration, 
angiogenesis, cytokine production and differ-
entiation, and another mentioned pathway is 
represented by mitogen-activated protein ki-
nases, like ERK, which governs the cell move-
ment by phosphorylating FAK and plays so far 
crucial roles in focal adhesion and cell migra-
tion. Thus, secretome enhances the prolifera-
tive and migratory abilities of various types of 
skin cells, such as fibroblasts, keratinocytes 
and vascular epithelial cells in the same way 
as MSCs do. Major components of the stem 
cell secretome were recognized as epidermal 
growth factor, basic fibroblast growth factor 
and hepatocyte growth factor, which could be 
responsible for promoting migration and pro-
liferation of skin cells, such as dermal fibro-
blasts, keratinocytes and vascular endothelial 
cells and so far for upregulation of appropriate 
signalling pathways, leading to the accelera-
tion of wound contraction [54]. The presence 
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of another epithelial growth factor, TGF-β, 
vascular endothelial derived growth factor, 
keratinocyte growth factor and others in sec-
retome of MSCs play an important role in 
wound healing [55].
In the clinical research, the conditioned me-
dium “АSС” (Adipose Stem Cells) was used as 
an agent for healing the patients’ skin wounds 
after a laser irradiation, and it was shown that 
the medium improved wound healing and re-
duced side effects of laser therapy [56]. The 
MSC-sec is profitably employed in situations, 
where bandages are not easily applied, e.g., to 
heal ulcers of ocular epithelium [57]. 
Secretomes of platelets [58] or peripheral 
blood mononuclear cells (PBMC) [59] also 
contain the components essential for wound 
healing. Platelets contribute to physiological 
hemostasis and pathological thrombo-inflam-
mation and are the first cells to respond to an 
injury. Platelets secretome is enriched in 
growth factors, chemokines, cytokines and 
other signalling molecules. These components 
have diverse effects on the biochemical, mo-
lecular and cellular environment at the wound 
site in the context of inflammation; recruitment 
of neutrophils, macrophages and fibroblasts; 
anti-microbial response; angiogenesis; extra-
cellular matrix synthesis etc. [60].
The secretome of apoptotic PBMCs ob-
tained by irradiation — APOSEC (APOptotic 
PBMC SECretome, a secretome from apop-
toticPBMCs) — had a number of cytokines, 
lipids, proteins, nanovesicles. In preclinical 
studies, this rich bioactive material had a high 
potential for regenerative therapies and treat-
ment of various diseases and chronic wounds 
[61, 62]. In Phase I research, it was shown that 
APOSEC did not cause complications, how-
ever, it did not affect the wound closing [63]. 
On the basis of a long-term research of the 
APOSEC preparation, the authors considered 
that elucidating the mechanism/s of skin re-
generation was impossible at that stage. These 
results show that, firstly, there is still much to 
learn about the secretome content, regulation, 
interaction and complementarity of the spe-
cific components in wound healing. Secondly, 
the environmental factors, such as general state 
of patient’s health, age, sex etc., affect the 
healing, and this ought to be taken into ac-
count. Thirdly, it is necessary to apply standard 
approaches to production and application of 
the preparations of clearly defined content with 
the expected mechanism of action. 
 In spite of still unfruitful clinical trials 
results, emerging MSC- and other secretome-
based non-cellular therapies have the future in 
regenerative medicine because of several ad-
vantages over cell-based technologies: (a) an 
overcome of the safety problem, potentially 
linked to living cell transplantation and in-
cluded immune compatibility, the possibility 
of tumorigenicity, embolism and a transfer of 
infections; (b) a prolonged store of the secre-
tome preparations without potentially toxic 
crioconservative agents with no loss of func-
tionality; (c) secretome is more practical for a 
clinical application, since it does not require 
the invasive protocols of cell acquisition; (d) a 
large-scale production of secretomes through 
specific cell lines in controlled lab conditions; 
(e) time and cost of keeping cultured SCs can 
be reduced; (f) the biological product, obtained 
for a therapeutic use, can be modified for get-
ting the desired cell effects.
 As mentioned above, the whole stem cell 
secretome contains a mixture of valuable bio-
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molecules. For clinical purposes, the identifica-
tion and production of the whole stem cell 
secretome in accordance with good manufac-
turing practice of single MSC-sec-components 
will be challenging in the nearest time. MSC-
secs-derived valuable therapeutics such as 
cytokines, growth factors, hormones, peptides, 
miRNA etc. are produced biotechnologically, 
using modern approaches such as culturing 
MSCs in 3D scaffolds, growing under influ-
ence of such stress factors as magnetic field, 
oxidation, hypoxia [55]. 
Extracellular membrane vesicles 
as potential novel therapeutics 
in regenerative medicine
Human cells secret several types of membrane 
vesicles with different physiological proper-
ties that include exosomes, microvesicles 
(known also as microparticles, shedding mi-
crovesicles) and apoptotic bodies [64]. The 
smallest of them are exosomes (30–100 nm), 
which originate from the late endosome mul-
tivesicular bodies (MVB) formed inside the 
eukaryotic cell to sort various transport vesi-
cles. Exosomes are secreted when MVBs in-
tegrate with plasma cell membrane and are 
released into the extracellular compartment. 
This process is regulated by the protein ma-
chinery known as the Endosomal Sorting 
Complex Required for Transport (ESCRT) 
system [65]. ESCRT-independent exosome 
formation relies on ceramide generation by 
neutral sphingomyelinase 2, a key cell signal-
ing enzyme. The microvesicles (MVs) are 
formed by “budding” of the cell membrane 
with a size from 60 to 1000 nm, and they also 
require for the ESCRT system together with 
scramblase and flippase activities [66]. Lastly, 
large complex vesicles, apoptotic bodies (500 
nm to 2 µm), are secreted through exocytosis 
by dying cells; this type of EMVs is out of 
this review. All types of EMVs are formed 
imperatively by phospholipid membranes and 
secreted by cells outwards. Nanovesicle bio-
genesis is different, and molecular cargo is 
different, respectively. For example, trans-
membrane proteins, such as tetraspanins 
(CD9, CD63, CD81) from the endosomal 
sorting complex, are mostly associated with 
exosomes, whereas proteins from the endo-
plasmic reticulum, Golgi, mitochondria or the 
nucleus are preferentially found in microves-
icles and rarely — in exosomes [67].
Theoretically, the heterogeneous popula-
tions of EMVs are produced by all known 
types of cells, from archaea to mammals. They 
are present in the body fluids, including blood, 
saliva, tears, urine, cerebrospinal and amni-
otic fluids, milk and sperm. EMVs, derived 
from different cells, have different activities 
associated with either cellular functions or 
pathological states, depending on their content. 
Having no metabolism and the capability to 
self-replenish, EMVs carry valuable cargo 
molecules produced by the host cells, such as 
proteins (cytokines, growth factors, transcrip-
tion factors, enzymes, receptors etc.) and nu-
cleic acids (messenger RNA, miRNA, long 
noncoding RNA, mitochondrial and chromo-
somal DNA) [64, 66] (Fig. 4). Recent studies 
have shown that EMVs carry membrane-de-
rived bioactive lipids (eicosanoids) that per-
form an important function in the immune 
system. EMVs protect bioactive lipids (as well 
as other biomolecules) from degradation and 
play a role in the transcellular synthesis of 
prostaglandins and leukotrienes [68]. 
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EMVs are recognized as mediators of para-
crine signals and play a role in cell-to-cell 
communications. EMVs can interact with target 
cells using different mechanisms, e.g., clathrin-
mediated endocytosis, micropinocytosis and 
lipid raft-dependent endocytosis [69]. In short- 
and long-distance communications, small non-
coding (nc) RNAs along with bioactive protein 
factors packed and carried by vesicles are the 
key modulators of biological effects in the 
target cells. Long noncoding RNAs induce 
epigenetic modifications in recipient cells by 
recruiting epigenetic regulators [70]. In 2013, 
J. Rothman, R. Schekman and T. Sudhof won 
the Nobel Prize in Physiology/Medicine for 
discovering molecular principles of the gov-
erned cargo molecules delivery to target cell 
by membrane vesicles. This event considerably 
promoted the research in biomedical area. Due 
to unique properties, such as nanoscale, a trans-
version of the blood-brain barrier and a penetra-
tion of dense structural tissue, EMVs became 
a promising tool for the treatment of a wide 
spectrum of diseases, either as unmodified 
agents or as functionalized carriers for targeted 
drug delivery. Noteworthy, the healing effects 
were observed in studies with both exosome 
and microvesicle populations, and often it was 
mentioned with no regard to the distinction 
between them. In the background of regenera-
tive medicine research, MSC-derived exosomes 
are the most studied and appear to be respon-
sible for many of the traits commonly associ-
ated with MSCs, including tissue healing. 
Many other types of cells also secrete exo-
somes, which are promi sing for healing.
Fig. 4. Biogenesis, molecular cargo and signalling of extracellular membrane vesicles (EMV). A — The EMVs can be 
secreted into the extracellular environment through either fusion of multivesicular bodies with the cell surface (exo-
somes) or budding pathway (microvesicles). B — Molecular composition of exosomes. Exosomes are membrane-
bound phospholipid nanovesicles secreted by all cell types. They bear cellular components, including mRNAs, miR-
NAs, DNAs, various proteins, lipids. C — EMVs trigger signalling pathways that suppress inflammation, modulate 
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Extracellular membrane vesicles of stem 
cells and progenitor cells in wound healing
EMVs, secreted by MSCs, mimic and reca-
pitulate some of the parent cell functions, such 
as self-guidance into the target/injured site, 
immunomodulation and reprogramming of 
cells required for the tissue regeneration [71]. 
Remarkably, exosomes were shown to possess 
procoagulatory activity, essential for healing 
the bleeding wounds [72]. In the wound heal-
ing process, EMVs take part at all stages of 
wound healing [69, 73]. EMVs derived from 
different sources demonstrated similar charac-
teristics in wound healing. The topical or sys-
temic use of exosomes and microvesicles 
showed their efficiency in non-healing wound 
treating at the same rate, as SCs did [74–78]. 
At the cellular level, EMVs administration has 
been found to enhance endothelial cell prolif-
eration and migration, tube formation, promot-
ing angiogenesis and blood vessel maturation, 
skin remodelling, resulting in suppressed myo-
fibroblast accumulation and reduced scar for-
mation in vivo. In other words, MSC-EMVs 
act directly upon epithelial cells, endothelial 
cells and fibroblasts during wound healing or 
via EMVs molecular cargo at a distance, mod-
ulating intracellular signalling pathways with-
in the recipient cells. Activation of signalling 
cascades resolves chronic inflammation (e.g., 
by the activating Signal Transducer and 
Activator of Transcription 3 (STAT3)/AKT 
(protein kinaseB) and promotes angiogenesis 
(e.g., via ERK1/2 or Wnt4 pathway, which 
induced β-catenin activation [79, 80] (see 
Fig. 4C). Exosomes promote synthesis of col-
lagen I and III at the early stage of wound 
healing, whereas at the late stage, exosomes 
prevent collagen deposition and scarring [81]. 
More specifically, such a regulation can be 
performed by regulatory molecules that medi-
ate a wound healing such as proteins, e.g., 
HSP90a, p-STAT3, p-AKT, p-P65 [82], and by 
small non-coding (nc)RNAs, regulating gene 
expression at the level of translation [83]. At 
the injury sites, ncRNAs contribute to the 
regulation of matrix remodelling, epithelial 
mesenchymal transitions and the attraction of 
fibroblasts. Additionally, ‘anti-inflammatory’ 
RNAs potentially orchestrate the resolution of 
inflammatory responses and immune allevia-
tion to facilitate healing processes. 
Exosomes originated from MSCs also have 
been shown as efficient therapeutics in the 
regeneration of joints, bones, a heart muscle 
after myocardial infarction, a brain traumatic 
injuries etc. [84–87]. 
Extracellular membrane vesicles 
of other cell types in wound healing
In addition to EMVs of stem and progenitor 
cells, the membrane vesicles of other cell types 
also have healing potential. Exosomes of plate-
lets are the most widespread EMVs in human 
peripheral blood (known as a platelet ‘dust’) 
and comprise more than a half of all the EMVs 
in blood. Platelet EMVs bear pro-coagulant 
anionic lipid needed for the formation of pro-
trombinase complex and other factors of 
wound healing [88]. Such nanostructures take 
part in several essential biological and patho-
logical processes through blood clotting, an-
giogenesis, inflammation, immunoregulation 
etc. [89]. Torreg gia ni and co-authors showed 
that the platelet exosomes contained main 
growth factors of parental cells and so far 
could be one of the effectors of the well-known 
action of the platelet-rich plasma (PRP) and 
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platelet lysate [90]. Based on this conclusion, 
the attempts to use them for a therapy of chron-
ic wounds have been undertaken. In the dia-
betic rat model, it was shown that platelet 
exosomes had properties similar to PRP: they 
improved cell proliferation, migration and an-
giogenesis in healing wounds [91]. Up to date 
(20.06.2018), the clinical trial (Phase 1) has 
been listed on the clinical trials website (https://
clinicaltrials.gov/), the purpose of which is to 
evaluate the effect of autologous EMVs prep-
aration from rich plasma on cutaneous wound 
healing.
More research is required to find new sour-
ces for the harvesting of EMVs with their 
further translation into clinical applications. 
Cheaper EMV-based therapeutics for non-
healing wounds may be found among vesi-
cleomes of safe human commensal microor-
ganisms, especially, for curing infected and 
rotting wounds. Outer membrane vesicles 
(OMVs) of gram-negative bacteria, rich in 
biologically active substances, are the major 
factor in their interaction with the macroorgan-
ism [92]. Proteomic and biochemical analyses 
have shown that they contain a variety of bac-
terial components from the outer membrane, 
like lipopolysaccharide (LPS) and lipoproteins, 
periplasmic proteins, DNA and RNA. The 
EMVs secretion mediates bacterial adaptation 
to various niches [93]. The surface OMV com-
ponents act as pathogen-associated molecular 
patterns and stimulate the innate immune re-
ceptors, such as Toll-like receptors and Nod-
like receptors, to modulate the innate immune 
responses. OMVs of human commensal gut 
bacteria have an anti-inflammatory effect, en-
hancing the T(reg) cells in the intestine and 
protecting against colitis [94]. OMVs are the 
vehicle that delivers LPS in host cells to trig-
ger the immune response [95]. Bacterial 
nanovesicles induce cytokine synthesis needed 
for the injured tissue regeneration and wound 
healing [96]. Importantly, bacterial OMVs, 
secreted by Burkholderia spp., inhibit the de-
velopment of antibiotic resistant bacteria as 
well as the production of a biofilm [97]. 
Besides, gram-negative bacteria (Сitrobacter 
sp., Enterobacter sp., Lysobacter sp. etc.) are 
known to produce a complex of bacteriolytic 
enzymes localized in the OMVs that are effi-
cient against gram-positive pathogens [98, 99]. 
Remarkably, there is no available information 
on the role of bacterial vesicles in tumorigeni-
city unlike exosomes, which appeared to im-
pact the process. Taking together, it is easy to 
predict the therapeutic potential of OMVs, 
loaded with bacteriolytic enzymes, against 
antibiotic-resistant bacteria (that infect open 
wounds and complicate the treatment process), 
as well as to imagine, how cheaper might be 
bacterial nanovesicle therapeutics in compari-
son with MSC-exosomes and MVs. 
Driving forces of exosome industry
The EMVs attract attention as possible ideal 
therapeutic agents because of their long circu-
lation time without the loss of the quantity and 
quality. Exosomes and microvesicles are non-
living creatures, and so far as therapeutics are 
advantageous over the cell-based technologies 
in regenerative medicine, especially, consider-
ing the safety problem. Unlike SCs, where 
there is the risk of spontaneous or induced 
transformation and necessity of the cytoge-
netic control, exosomes cannot differentiate 
into any cells. Exosomes are much easier to 
manipulate and store. In contrast with syn-
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thetic drugs, exosomes are physiological and 
perceived as own, so they can systemically, 
even overcoming the hematoencephalic bar-
rier, deliver small (femtomole) doses of bio-
molecules or drugs [100]. Finally, using the 
autologous exosomes reduces the risks of 
pathogen transfer and immune non-compati-
bility. 
 Bioengineering is in use to construct smart-
vectors based on EMVs for different types of 
healing factor delivery that would selectively 
enter certain cells and correct the healing pro-
cess (see reviews [101, 102]). Healing factors 
can be loaded into the exosome interior, in the 
periplasmic space or represented as superficial 
constructs (displays) on the EMV sur-
face [103]. Currently, the EMV engineering 
for enhanced therapeutic effect has not yet 
been extensively pursued in the area of wound 
healing. However, there are three approaches 
elaborated to improve efficiency and specific-
ity of the EMVs action, when needed: a) a 
treatment of cells-donors of EMVs with ther-
apeutic agents; b) a genetic modification of 
EMVs cells-donors; c) a direct modification 
of EMVs. For example, the preconditioned 
with lipopolysaccharide MSCs showed en-
hanced paracrine effects and the therapeutic 
efficacy for chronic inflammation and wound 
healing via the loading of miRNAlet-7b, which 
so far mitigated inflammation in the wound 
through the regulation of anti-inflammatory 
cytokines expression [104]. Depending on the 
etiology of non-healing wounds, exosomes can 
be filled with different miRNA, enhancing the 
signalling pathways, responsible for healing, 
e.g., with miRNA-126–3p, which stimulates 
а fibroblast proliferation [105]. Placing protein 
ligands on the surface of EMVs allows a de-
livery of molecular cargo into the target 
site [103].
Exosomes are easy to enter the body, in 
particular, by systemic or local therapy. The 
reported studies have utilized both local and 
systemic (intravenous) administration in 
wound healing. Locally applied EMVs have 
been delivered by direct topical application, 
injection into or around the wound and integra-
tion into biomaterials. For wound healing 
topical application, e.g., sponges or dressings, 
filled with EMVs are in use. Biocompatible 
carriers are successfully employed to deliver 
EMVs and release their contents in controlled 
quantities into the wound. Recent researches 
have shown that for topical application, poly-
saccharide-based matrices are the efficient 
carriers of EMVs. For example, a combination 
of MSC-exosomes and chitosan-derived hy-
drogel can efficiently help to heal the skin 
wounds in diabetic rats by reepithelization, 
synthesis and remodelling of collagen, angio-
genesis and production of neurons [106]. The 
in vivo diabetic wound healing study showed 
that the treatments using platelet exosomes 
loaded into chitosan-derived hydrogel, en-
hanced with polysaccharide from the rhizomes 
of Curcuma zedoaria, accelerated wound con-
traction and decreased ulcer [107].
 At present, the interest in the application 
of exosomes and other membrane vesicles in 
regenerative medicine is constantly growing. 
Market forces driving growth of the exosome 
industry have been expanding over the past 
two years, with increasing investment flowing 
into research, development of tools, new ther-
apeutics, entering various stages of develop-
ment. First exosome biotech companies from 
the USA and the European Union appeared on 
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the world market in 2015. Using academic and 
commercial research as a background, they 
started the exosome bioproducts manufactur-
ing for regenerative medicine. The most ben-
efited are patients with posttraumatic syn-
dromes and degenerative diseases. Exosome-
based therapeutics are in use also for chronic 
wounds healing. For example, the ExoWound 
product, based on the exosomes of umbilical 
cord blood MSCs produced by Exogenus 
Therapeutics from Portugal has recently 
launched on the European market (http://www.
exogenus-t.com/). Another exosome-based 
product known as XoGlo™ for topical applica-
tion in wound and burn healing is practicized 
by Kimera Lab (the USA) (http://www.kimer-
alabs.com/). 
Meanwhile, the exact mechanisms of indi-
rect reparative effect of EMVs remain insuf-
ficiently studied. It also remains to elucidate, 
whether morphology, integrity and interaction 
of EMVs with target cells and their biological 
activities do not alter during the obligatory 
purification from viruses. The rate of the re-
generative capacities of EMVs depends on the 
type of mother cell, and it remains unclear, 
which donor cell type provides the most pow-
erful effect. Despite the emerging possibilities 
of treatment by EMVs, the novel nature of 
EMV-mediated therapy causes concern on their 
safety. The International Society for 
Extracellular Vesicles established the minimal 
set of biochemical, biophysical and functional 
standards for the EMV research, which can be 
used in the countries where this background is 
not developed. Therefore, the obtaining of 
expected positive results from clinical trials of 
EMVs as therapeutics requires in-depth re-
search for reaching their full potential.
Tissue products in wound healing
Extracellular matrices are in use in regenera-
tive medicine for wound healing and tissue 
regeneration in various traumas. In addition to 
their use as scaffolds for tissue reconstruction, 
fibrous matrices are considered as valuable 
pools of bioactive molecules that can mediate 
tissue regeneration through modulating the 
immune response and recruiting and stimulat-
ing stem and progenitor cells [108]. The tem-
porary organs, e.g., a placental complex, nec-
essary for the development and birth of the 
fetus, are known as such matrices. The amni-
otic membrane is the most used in clinical 
practice within hundreds of years. The amnion 
is a placental membrane that envelops the 
fetus and is found to be useful in therapy due 
to its unique structure and valuable contents 
for the damaged tissue regeneration. The mem-
brane is rich in collagen, contains no blood 
and lymph vessels or nerves and has very low 
antigenicity. The transplanting of the mem-
brane promotes reepithelization, inhibition of 
inflammation and scarring, relieves pain and 
so far it is especially efficient in burns healing. 
Amniotic tissue is also used in the treatment 
of diabetic wounds, in particular, in the lower 
limb or other wounds resistant to traditional 
therapy [109, 110]. Current data show that the 
remarkable healing effect occurs because of 
the amnion products, which stimulate secretion 
of growth factors, cytokines, proteases and 
increase synthesis of stromal cell factors [111].
The placental extracts obtained by lysis of 
the placental tissue are rich in amino acids, 
proteins, minerals, steroid hormones, cytokines 
etc. and have curing effects. Placental products 
are used in the treatment of traumatic and 
chronic wounds, as well as non-healing ulcers 
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and burns, due to the bioactive substances with 
anti-inflammatory properties, which also pro-
mote reepithelization, reduce infiltration and 
relieve a pain syndrome through the inhibition 
of cyclooxygenase-2. The extracts also have 
immunoregulative, neuroprotective, anti-aller-
gic and antitumor properties. Through their 
complex action, placental extracts are promis-
ing agents in the treatment of diabetic neu-
ropathy and angiopathy [112]. The mechanism 
of placental extract action depends on the pres-
ence of bioactive corticotrophin-releasing fac-
tor that possibly increases the production of 
TGF-β and reduces the level of proinflamma-
tory TNF-α [113].
In spite of the remarkable composition of 
bioactive substances, the placental tissue prod-
ucts do not overwhelm the world market of 
therapeutics, e.g., for wound healing. However, 
the placental tissue extracts were used in the 
development of the burn wound treatment 
therapy at the Institute of Cell Therapy (Kyiv, 
Ukraine). The application of placental tissues 
in burn treatment allows shortening the time 
before autodermoplasty, stimulates granulation 
and epithelization and reduces inflammatory 
reaction and intoxication (http://www.stem-
cellclinic.com). 
Conclusion
Regenerative medicine advanced therapy opens 
new possibilities in the treatment of wounds 
resistant to traditional therapy. Stem cells are 
known as highly relevant agents for healing 
chronic and non-healing wounds due to valu-
able secretomia, self-guidance into the target 
place, self-regeneration and differentiation. 
This novel approach in regenerative medicine 
is especially indispensable in relation to aging 
and age-related diseases, because of the SCs 
capability to replace lost cells for regeneration 
of tissues and organs. Despite the successes in 
applying SCs and progenitor cells, some bar-
riers prevent efficient therapeutic action, e.g., 
limits of transplantation areas and a poor SCs 
engrafting into the recipient injured tissues. 
Current approaches, such as preconditioning 
and using the next generation SCs, modulation 
of the SC-secretomes, using extracellular mem-
brane vesicles lead to maximization of the SC 
bioeffects. EMVs of different origin can be 
used in the treatment of non-healing wounds 
either by themselves or in combination with 
other therapeutics. On the background of the 
newest reconstructive technologies, the tissue 
products remain reliable means for the rescue 
of patients with chronic ulcers. Considering 
that the mechanisms of wound healing may 
differ, depending on the localization, size and 
depth of the wound, infection by pathogenic 
microorganisms, patient immune system state, 
there is an urgent need to develop personalized 
medicine for healing patients in accordance 
with the individual protocols based on the pa-
tient’s advanced examination.
REFERENCES
1. Watt SM, Pleat JM. Stem cells, niches and scaffolds: 
Applications to burns and wound care. Adv Drug 
Deliv Rev. 2018;123:82–106.
2. Havran WL, Jameson JM. Epidermal T cells and 
wound healing. J Immunol. 2010;184(10):5423–8.
3. Leavitt T, Hu M, Marshall C, Barnes L, Longaker M, 
Lorenz P. Stem cells and chronic wound healing: 
state of the art. Chronic Wound Care Manag Res. 
2016, 3:7–27.
4. Gottrup F, Apelqvist J, Price P; European Wound 
Management Association Patient Outcome Group. 
Outcomes in controlled and comparative studies on 
189
Regenerative medicine advanced therapy for the non-healing cutaneous wound
non-healing wounds: recommendations to improve 
the quality of evidence in wound management. 
J Wound Care. 2010;19(6):237–68.
5. Gaur M, Dobke M, Lunyak VV. Mesenchymal stem 
cells from adipose tissue in clinical applications for 
dermatological indications and skin aging. Int J Mol 
Sci. 2017;18(1). pii: E208. 
6. Na YK, Ban JJ, Lee M, Im W, Kim M. Wound heal-
ing potential of adipose tissue stem cell extract. 
Biochem Biophys Res Commun. 2017;485(1):30–34.
7. Chen B, Li Q, Zhao B, Wang Y. Stem Cell-Derived 
extracellular vesicles as a novel potential therapeu-
tic tool for tissue repair. Stem Cells Transl Med. 
2017;6(9):1753–1758.
8. Guo SC, Tao SC, Yin WJ, Qi X, Yuan T, Zhang CQ. 
Exosomes derived from platelet-rich plasma pro-
mote the re-epithelization of chronic cutaneous 
wounds via activation of YAP in a diabetic rat mo-
del. Theranostics. 2017;7(1):81–96. 
9. Valle-Prieto A, Conget PA. Human mesenchymal 
stem cells efficiently manage oxidative stress. Stem 
Cells Dev. 2010;19(12):1885–93.
10. Li N, Hua J. Interactions between mesenchymal 
stem cells and the immune system. Cell Mol Life 
Sci. 2017;74(13):2345–2360.
11. Shende P, Gupta H, Gaud RS. Cytotherapy using 
stromal cells: Current and advance multi-treatment 
approaches. Biomed Pharmacother. 2018;97:38–44.
12. Takahashi K, Yamanaka S. Induction of pluripotent 
stem cells from mouse embryonic and adult fibro-
blast cultures by defined factors. Cell. 
2006;126(4):663–76.
13. Lobo SE, Leonel LC, Miranda CM, Coelho TM, 
Ferreira GA, Mess A, Abrão MS, Miglino MA. The 
placenta as an organ and a source of stem cells and 
extracellular matrix: a review. Cells Tissues Organs. 
2016;201(4):239–52.
14. Yoder MC. Endothelial stem and progenitor cells 
(stem cells): (2017 Grover Conference Series). Pulm 
Circ. 2018;8(1):2045893217743950.
15. Mahla RS. Stem Cells applications in regenerative 
medicine and disease therapeutics. Int J Cell Biol. 
2016;2016:6940283.
16. Hyldig K, Riis S, Pennisi CP, Zachar V, Fink T. 
Implications of extracellular matrix production by 
adipose tissue-derived stem cells for development 
of wound healing therapies. Int J Mol Sci. 
2017;18(6). pii: E1167.
17. Omole AE, Fakoya AOJ. Ten years of progress and 
promise of induced pluripotent stem cells: historical 
origins, characteristics, mechanisms, limitations, 
and potential applications. PeerJ. 2018;6:e4370. 
18. Bollini S, Silini AR, Banerjee A, Wolbank S, Balbi C, 
Parolini O. Cardiac Restoration Stemming From 
the Placenta Tree: Insights From Fetal and Perinatal 
Cell Biology. Front Physiol. 2018;9:385.
19. Dominici M, Le Blanc K, Mueller I, Slaper-Corten-
bach I, Marini F, Krause D, Deans R, Keating A, 
Prockop Dj, Horwitz E. Minimal criteria for defin-
ing multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position 
statement. Cytotherapy. 2006;8(4):315–7.
20. Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. 
Wound healing — A literature review. An Bras 
Dermatol. 2016;91(5):614–620.
21. Wong VW, Levi B, Rajadas J, Longaker MT, Gurt-
ner GC. Stem cell niches for skin regeneration. Int 
J Biomater. 2012;2012:926059.
22. Badiavas EV, Falanga V. Treatment of chronic 
wounds with bone marrow-derived cells. Arch Der-
matol. 2003;139(4):510–6.
23. Hyldig K, Riis S, Pennisi CP, Zachar V, Fink T. 
Implications of Extracellular Matrix Production by 
Adipose Tissue-Derived Stem Cells for Develop-
ment of Wound Healing Therapies. Int J Mol Sci. 
2017;18(6). pii: E1167.
24. Chan XY, Black R, Dickerman K, Federico J, 
Lévesque M, Mumm J, Gerecht S. Three-Dimension-
al Vascular Network Assembly From Diabetic Pa-
tient-Derived Induced Pluripotent Stem Cells. Arte-
rioscler Thromb Vasc Biol. 2015;35(12):2677–85.
25. Kim JY, Suh W. Stem cell therapy for dermal wound 
healing. Int J Stem Cells. 2010;3(1):29–31.
26. Zeng X, Tang Y, Hu K, Jiao W, Ying L, Zhu L, Liu J, 
Xu J. Three-week topical treatment with placenta-
derived mesenchymal stem cells hydrogel in a pa-
tient with diabetic foot ulcer: A case report. Medi-
cine (Baltimore). 2017;96(51):e9212.
27. Griffin MF, Butler PE, Seifalian AM, Kalaskar DM. 
Control of stem cell fate by engineering their micro 
190
I. V. Orlovska, A. H. Haidak, N. O. Kozyrovska
and nanoenvironment. World J Stem Cells. 
2015;7(1):37–50.
28. Bello AB, Park H, Lee SH. Current approaches in 
biomaterial-based hematopoietic stem cell niches. 
Acta Biomater. 2018;72:1–15.
29. Luo X, Zeng T, He S, Lin C. The Combined effects 
of bone marrow-derived mesenchymal stem cells 
and microporous porcine acellular dermal matrices 
on the regeneration of skin accessory cells in vivo. 
J Burn Care Res. 2018;39(4):481–490.
30. Dash BC, Xu Z, Lin L, Koo A, Ndon S, Berthiaume F, 
Dardik A, Hsia H. Stem Cells and engineered scaf-
folds for regenerative wound healing. Bioengineer-
ing (Basel). 2018;5(1). pii: E23. 
31. Xavier Acasigua GA, de Olyveira GM, Manzine 
Costa LM, Braghirolli DI, Medeiros Fossati AC, 
Guastaldi AC, Pranke P, Daltro Gde C, Basmaji P. 
Novel chemically modified bacterial cellulose nano-
composite as potential biomaterial for stem cell 
therapy applications. Curr Stem Cell Res Ther. 
2014;9(2):117–23.
32. Rödling L, Schwedhelm I, Kraus S, Bieback K, 
Hansmann J, Lee-Thedieck C. 3D models of the 
hematopoietic stem cell niche under steady-state 
and active conditions. Sci Rep. 2017;7(1):4625.
33. Matsumine H, Numakura K, Tsunoda S, Wang H, 
Matsumine R, Climov M, Giatsidis G, Sukhatme VP, 
Orgill DP. Adipose-derived aldehyde dehydroge-
nase-expressing cells promote dermal regenerative 
potential with collagen-glycosaminoglycan scaffold. 
Wound Repair Regen. 2017;25(1):109–119.
34. Yi S, Ding F, Gong L, Gu X. Extracellular Matrix 
Scaffolds for Tissue Engineering and Regenerative 
Medicine. Curr Stem Cell Res Ther. 2017;12(3):233–
246. Review.
35. He P, Zhao J, Zhang J, Li B, Gou Z, Gou M, Li X. 
Bioprinting of skin constructs for wound healing. 
Burns Trauma. 2018;6:5.
36. Nolta JA. “Next-generation” mesenchymal stem or 
stromal cells for the in vivo delivery of bioactive 
factors: progressing toward the clinic. Transfusion. 
2016;56(4):15S–7S.
37. Fierro FA, Kalomoiris S, Sondergaard CS, Nolta JA. 
Effects on proliferation and differentiation of mul-
tipotent bone marrow stromal cells engineered to 
express growth factors for combined cell and gene 
therapy. Stem Cells. 2011;29(11):1727–37.
38. Hourd P, Williams DJ. Scanning the horizon for high 
value-add manufacturing science: Accelerating 
manufacturing readiness for the next generation of 
disruptive, high-value curative cell therapeutics. 
Cytotherapy. 2018;20(5):759–767.
39. Merkert S, Martin U. Targeted genome engineering 
using designer nucleases: State of the art and prac-
tical guidance for application in human pluripotent 
stem cells. Stem Cell Res. 2016;16(2):377–86.
40. Santos DP, Kiskinis E, Eggan K, Merkle FT. Com-
prehensive Protocols for CRISPR/Cas9-based Gene 
Editing in Human Pluripotent Stem Cells. Curr 
Protoc Stem Cell Biol. 2016;38:5B.6.1–5B.6.60.
41. Kim SI, Matsumoto T, Kagawa H, Nakamura M, 
Hirohata R, Ueno A, Ohishi M, Sakuma T, Soga T, 
Yamamoto T, Woltjen K. Microhomology-assisted 
scarless genome editing in human iPSCs. Nat Com-
mun. 2018;9(1):939. 
42. Kosaric N, Srifa W, Gurtner GC, Porteus MH. Ab-
stract 100: Human Mesenchymal Stromal Cells 
Engineered to Overexpress PDGF-B Using CRIS-
PR/Cas9/rAAV6-based Tools Improve Wound Heal-
ing. Plastic and Reconstructive Surgery Global 
Open. 2017;5(4 Suppl):74. 
43. Lau RWK, Wang B, Ricardo SD. Gene editing of 
stem cells for kidney disease modelling and thera-
peutic intervention. Nephrology (Carlton). 2018.
44. Hu C, Li L. Preconditioning influences mesenchymal 
stem cell properties in vitro and in vivo. J Cell Mol 
Med. 2018;22(3):1428–1442.
45. Zitvogel L, Regnault A, Lozier A, Wolfers J, Fla-
ment C, Tenza D, Ricciardi-Castagnoli P, Raposo G, 
Amigorena S. Eradication of established murine 
tumors using a novel cell-free vaccine: dendritic 
cell-derived exosomes. Nat Med. 1998;4(5):594–600.
46. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fer-
nandez R. Mesenchymal Stem Cell Secretome: To-
ward Cell-Free Therapeutic Strategies in Regenera-
tive Medicine. Int J Mol Sci. 2017;18(9). pii: E1852.
47. Cunningham CJ, Redondo-Castro E, Allan SM. The 
therapeutic potential of the mesenchymal stem cell 
secretome in ischaemic stroke. J Cereb Blood Flow 
Metab. 2018:271678X18776802. 
191
Regenerative medicine advanced therapy for the non-healing cutaneous wound
48. Walter MN, Wright KT, Fuller HR, MacNeil S, 
Johnson WE. Mesenchymal stem cell-conditioned 
medium accelerates skin wound healing: an in vitro 
study of fibroblast and keratinocyte scratch assays. 
Exp Cell Res. 2010;316(7):1271–81.
49. Bartaula-Brevik S, Bolstad AI, Mustafa K, Peder-
sen T. Secretome of mesenchymal stem cells grown 
in hypoxia accelerates wound healing and vessel 
formation in vitro. Int J Stem Cell Res Ther. 2017; 
4(1):1–9.
50. Jun EK, Zhang Q, Yoon BS, Moon JH, Lee G, 
Park G, Kang PJ, Lee JH, Kim A, You S. Hypoxic 
conditioned medium from human amniotic fluid-
derived mesenchymal stem cells accelerates skin 
wound healing through TGF-β/SMAD2 and PI3K/
Akt pathways. Int J Mol Sci. 2014;15(1):605–28.
51. Chen L, Xu Y, Zhao J, Zhang Z, Yang R, Xie J, Liu X, 
Qi S. Conditioned medium from hypoxic bone mar-
row-derived mesenchymal stem cells enhances 
wound healing in mice. PLoS One. 2014;9(4):e96161.
52. Chen J, Crawford R, Chen C, Xiao Y. The key 
regulatory roles of the PI3K/Akt signaling pathway 
in the functionalities of mesenchymal stem cells and 
applications in tissue regeneration. Tissue Eng 
Part B Rev. 2013;19(6):516–28.
53. Huang C, Jacobson K, Schaller MD. MAP kinases 
and cell migration. J Cell Sci. 2004;117(Pt 20):4619–
28.
54. Park SR, Kim JW, Jun HS, Roh JY, Lee HY, Hong IS. 
Stem Cell Secretome and Its Effect on Cellular 
Mechanisms Relevant to Wound Healing. Mol Ther. 
2018;26(2):606–617.
55. Abbasi-Malati Z, Roushandeh AM, Kuwahara Y, 
Roudkenar MH. Mesenchymal Stem Cells on Ho-
rizon: A New Arsenal of Therapeutic Agents. Stem 
Cell Rev. 2018;14(4):484–499.
56. Zhou BR, Xu Y, Guo SL, Xu Y, Wang Y, Zhu F, Per-
matasari F, Wu D, Yin ZQ, Luo D. The effect of 
conditioned media of adipose-derived stem cells on 
wound healing after ablative fractional carbon di-
oxide laser resurfacing. Biomed Res Int. 
2013;2013:519126. 
57. Bermudez MA, Sendon-Lago J, Eiro N, Treviño M, 
Gonzalez F, Yebra-Pimentel E, Giraldez MJ, Ma-
cia M, Lamelas ML, Saa J, Vizoso F, Perez-Fernan-
dez R. Corneal epithelial wound healing and bacte-
ricidal effect of conditioned medium from human 
uterine cervical stem cells. Invest Ophthalmol Vis 
Sci. 2015;56(2):983–92.
58. Golebiewska EM, Poole AW. Platelet secretion: 
From haemostasis to wound healing and beyond. 
Blood Rev. 2015;29(3):153–62.
59. Holzinger C, Zuckermann A, Kopp C, Schöllham-
mer A, Imhof M, Zwölfer W, Baumgartner I, Ma-
gometschnigg H, Weissinger E, Wolner E. Treatment 
of non-healing skin ulcers with autologous acti-
vated mononuclear cells. Eur J Vasc Surg. 
1994;8(3):351–6.
60. Sekhon UD, Gupta AS. Platelets and platelet-inspired 
biomaterials technologies in wound healing applica-
tions. ACS Biomaterials Science & Engineering. 
2018; 4(4): 1176–92.
61. Beer L, Zimmermann M, Mitterbauer A, Ellinger A, 
Gruber F, Narzt MS, Zellner M, Gyöngyösi M, 
Madlener S, Simader E, Gabriel C, Mildner M, 
Ankersmit HJ. Analysis of the Secretome of Apop-
totic Peripheral Blood Mononuclear Cells: Impact 
of Released Proteins and Exosomes for Tissue Re-
generation. Sci Rep. 2015;5:16662.
62. Hacker S, Mittermayr R, Nickl S, Haider T, Lebherz-
Eichinger D, Beer L, Mitterbauer A, Leiss H, Zim-
mermann M, Schweiger T, Keibl C, Hofbauer H, 
Gabriel C, Pavone-Gyöngyösi M, Redl H, 
Tschachler E, Mildner M, Ankersmit HJ. Paracrine 
Factors from Irradiated Peripheral Blood Mono-
nuclear Cells Improve Skin Regeneration and An-
giogenesis in a Porcine Burn Model. Sci Rep. 
2016;6:25168. 
63. Simader E, Traxler D, Kasiri MM, Hofbauer H, 
Wolzt M, Glogner C, Storka A, Mildner M, Gouya G, 
Geusau A, Fuchs C, Eder C, Graf A, Schaden M, 
Golabi B, Aretin MB, Suessner S, Gabriel C, Klepet-
ko W, Tschachler E, Ankersmit HJ. Safety and toler-
ability of topically administered autologous, apop-
totic PBMC secretome (APOSEC) in dermal 
wounds: a randomized Phase 1 trial (MARSYAS I). 
Sci Rep. 2017;7(1):6216.
64. van Niel G, D’Angelo G, Raposo G. Shedding light 
on the cell biology of extracellular vesicles. Nat Rev 
Mol Cell Biol. 2018;19(4):213–228.
192
I. V. Orlovska, A. H. Haidak, N. O. Kozyrovska
65. Colombo M, Raposo G, Théry C. Biogenesis, secre-
tion, and intercellular interactions of exosomes and 
other extracellular vesicles. Annu Rev Cell Dev Biol. 
2014;30:255–89.
66. Beer KB, Rivas-Castillo J, Kuhn K, Fazeli G, Kar-
mann B, Nance JF, Stigloher C, Wehman AM. Ex-
tracellular vesicle budding is inhibited by redundant 
regulators of TAT-5 flippase localization and phos-
pholipid asymmetry. Proc Natl Acad Sci U S A. 
2018;115(6):E1127–E1136.
67. Shen L-M, Quan L, Liu J. Tracking exosomes in 
vitro and in vivo to elucidate their physiological 
functions: implications for diagnostic and therapeu-
tic nanocarriers. ACS Appl Nano Mater. 2018, 
1(6):2438–48.
68. Boilard E. Extracellular vesicles and their content 
in bioactive lipid mediators: more than a sack of 
microRNA. J Lipid Res. 2018. pii: jlr.R084640.
69. Laberge A, Arif S, Moulin VJ. Microvesicles: Inter-
cellular messengers in cutaneous wound healing. 
J Cell Physiol. 2018;233(8):5550–5563.
70. Fatima F, Nawaz M. Vesiculated long non-coding 
rnas: offshore packages deciphering trans-regulation 
between cells, cancer progression and resistance to 
therapies. Noncoding RNA. 2017;3(1). pii: E10.
71. Silva AM, Teixeira JH, Almeida MI, Gonçalves RM, 
Barbosa MA, Santos SG. Extracellular Vesicles: Im-
munomodulatory messengers in the context of tissue 
repair/regeneration. Eur J Pharm Sci. 2017;98:86–95.
72. Yu Y, Gool E, Berckmans RJ, Coumans FAW, Bar-
endrecht AD, Maas C, van der Wel NN, Altevogt P, 
Sturk A, Nieuwland R. Extracellular vesicles from 
human saliva promote hemostasis by delivering 
coagulant tissue factor to activated platelets. 
J Thromb Haemost. 2018;16(6):1153–1163.
73. Cabral J, Ryan AE, Griffin MD, Ritter T. Extracel-
lular vesicles as modulators of wound healing. Adv 
Drug Deliv Rev. 2018;129:394–406.
74. Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exo-
some: A novel cell-free therapy for cutaneous re-
generation. Cytotherapy. 2018;20(3):291–301.
75. Golchin A, Hosseinzadeh S, Ardeshirylajimi A. The 
exosomes released from different cell types and their 
effects in wound healing. J Cell Biochem. 
2018;119(7):5043–5052.
76. Zhao B, Zhang Y, Han S, Zhang W, Zhou Q, Guan H, 
Liu J, Shi J, Su L, Hu D. Exosomes derived from 
human amniotic epithelial cells accelerate wound 
healing and inhibit scar formation. J Mol Histol. 
2017;48(2):121–132.
77. Shi Q, Qian Z, Liu D, Sun J, Wang X, Liu H, Xu J, 
Guo X. GMSC-derived exosomes combined with a 
chitosan/silk hydrogel sponge accelerates wound 
healing in a diabetic rat skin defect model. Front 
Physiol. 2017;8:904.
78. Li X, Jiang C, Zhao J. Human endothelial progeni-
tor cells-derived exosomes accelerate cutaneous 
wound healing in diabetic rats by promoting endo-
thelial function. J Diabetes Complications. 
2016;30(6):986–92.
79. Zhang J, Chen C, Hu B, Niu X, Liu X, Zhang G, 
Zhang C, Li Q, Wang Y. Exosomes Derived from 
Human Endothelial Progenitor Cells Accelerate 
Cutaneous Wound Healing by Promoting Angiogen-
esis Through Erk1/2 Signaling. Int J Biol Sci. 
2016;12(12):1472–1487.
80. Zhang B, Wu X, Zhang X, Sun Y, Yan Y, Shi H, Zhu Y, 
Wu L, Pan Z, Zhu W, Qian H, Xu W. Human um-
bilical cord mesenchymal stem cell exosomes en-
hance angiogenesis through the Wnt4/β-catenin 
pathway. Stem Cells Transl Med. 2015;4(5):513–22.
81. Hu L, Wang J, Zhou X, Xiong Z, Zhao J, Yu R, 
Huang F, Zhang H, Chen L. Exosomes derived from 
human adipose mensenchymal stem cells accelerates 
cutaneous wound healing via optimizing the char-
acteristics of fibroblasts. Sci Rep. 2016;6:32993.
82. Li W, Sahu D, Tsen F. Secreted heat shock protein-90 
(Hsp90) in wound healing and cancer. Biochim 
Biophys Acta. 2012;1823(3):730–41.
83. Fatima F, Ekstrom K, Nazarenko I, Maugeri M, 
Valadi H, Hill AF, Camussi G, Nawaz M. Non-
coding RNAs in Mesenchymal Stem Cell-Derived 
Extracellular Vesicles: Deciphering Regulatory 
Roles in Stem Cell Potency, Inflammatory Resolve, 
and Tissue Regeneration. Front Genet. 2017;8:161.
84. Bjørge IM, Kim SY, Mano JF, Kalionis B, Chrza-
nowski W. Extracellular vesicles, exosomes and 
shedding vesicles in regenerative medicine - a new 
paradigm for tissue repair. Biomater Sci. 
2017;6(1):60–78.  
193
Regenerative medicine advanced therapy for the non-healing cutaneous wound
85. Adamiak M, Sahoo S. Exosomes in Myocardial 
Repair: Advances and Challenges in the Develop-
ment of Next-Generation Therapeutics. Mol Ther. 
2018;26(7):1635–1643.
86. Giebel B, Kordelas L, Börger V. Clinical potential 
of mesenchymal stem/stromal cell-derived extracel-
lular vesicles. Stem Cell Investig. 2017;4:84. 
87. Rufino-Ramos D, Albuquerque PR, Carmona V, 
Perfeito R, Nobre RJ, Pereira de Almeida L. Extra-
cellular vesicles: Novel promising delivery systems 
for therapy of brain diseases. J Control Release. 
2017;262:247–258.
88. Varon D, Shai E. Platelets and their microparticles 
as key players in pathophysiological responses. 
J Thromb Haemost. 2015;13 Suppl 1:S40–6.
89. Tao SC, Guo SC, Zhang CQ. Platelet-derived Ex-
tracellular Vesicles: An Emerging Therapeutic Ap-
proach. Int J Biol Sci. 2017;13(7):828–834.
90. Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglìo SR, 
Baldini N. Exosomes: novel effectors of human plate-
let lysate activity. Eur Cell Mater. 2014;28:137-51;
91. Guo SC, Tao SC, Yin WJ, Qi X, Yuan T, Zhang CQ. 
Exosomes derived from platelet-rich plasma pro-
mote the re-epithelization of chronic cutaneous 
wounds via activation of YAP in a diabetic rat mod-
el. Theranostics. 2017;7(1):81–96.
92. Jan AT. Outer Membrane Vesicles (OMVs) of Gram-
negative Bacteria: A Perspective Update. Front 
Microbiol. 2017;8:1053.
93. Tsatsaronis JA, Franch-Arroyo S, Resch U, Char-
pentier E. Extracellular Vesicle RNA: A Universal 
Mediator of Microbial Communication? Trends 
Microbiol. 2018;26(5):401–410.
94. Shen Y, Giardino Torchia ML, Lawson GW, Karp CL, 
Ashwell JD, Mazmanian SK. Outer membrane ves-
icles of a human commensal mediate immune regu-
lation and disease protection. Cell Host Microbe. 
2012;12(4):509–20.
95. Vanaja SK, Russo AJ, Behl B, Banerjee I, Yanko-
va M, Deshmukh SD, Rathinam VAK. Bacterial 
Outer Membrane Vesicles Mediate Cytosolic Local-
ization of LPS and Caspase-11 Activation. Cell. 
2016;165(5):1106–1119.
96. Baker S, Davitt C, Morici L. Gram-negative bacte-
rial outer membrane vesicles inhibit growth of 
multidrug-resistant organisms and induce wound-
healing cytokines. Open Forum Infect Dis. 2016, 
3(1): 2242.
97. Nieves W, Petersen H, Judy BM, Blumentritt CA, 
Russell-Lodrigue K, Roy CJ, Torres AG, Morici LA. 
A Burkholderia pseudomallei outer membrane ves-
icle vaccine provides protection against lethal sepsis. 
Clin Vaccine Immunol. 2014;21(5):747–54.
98. Li Z, Clarke AJ, Beveridge TJ. Gram-negative bac-
teria produce membrane vesicles which are capable 
of killing other bacteria. J Bacteriol. 
1998;180(20):5478–83.
99. Kudryakova IV, Shishkova NA, Vasilyeva NV. Outer 
membrane vesicles of Lysobacter sp. XL1: bioge-
nesis, functions, and applied prospects. Appl Micro-
biol Biotechnol. 2016;100(11):4791–801.
100. Rani S, Ritter T. The Exosome — A Naturally 
Secreted Nanoparticle and its Application to Wound 
Healing. Adv Mater. 2016;28(27):5542–52.
101. Gilligan KE, Dwyer RM. Engineering Exosomes for 
Cancer Therapy. Int J Mol Sci. 2017;18(6). pii: E1122.
102. Armstrong JP, Holme MN, Stevens MM. Re-Engi-
neering Extracellular Vesicles as Smart Nanoscale 
Therapeutics. ACS Nano. 2017;11(1):69–83.
103. Tao SC, Guo SC, Zhang CQ. Modularized Extracel-
lular Vesicles: The Dawn of Prospective Persona-
lized and Precision Medicine. Adv Sci (Weinh). 
2018;5(2):1700449.
104. Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, 
Zhao Y, Liu H, Fu X, Han W. LPS-preconditioned 
mesenchymal stromal cells modify macrophage 
polarization for resolution of chronic inflammation 
via exosome-shuttled let-7b. J Transl Med. 
2015;13:308.
105. Akao Y, Iio A, Itoh T, Noguchi S, Itoh Y, Ohtsuki Y, 
Naoe T. Microvesicle-mediated RNA molecule de-
livery system using monocytes/macrophages. Mol 
Ther. 2011;19(2):395–9.
106. Tao SC, Guo SC, Li M, Ke QF, Guo YP, Zhang CQ. 
Chitosan Wound Dressings Incorporating Exosomes 
Derived from MicroRNA-126-Overexpressing Sy-
novium Mesenchymal Stem Cells Provide Sustained 
Release of Exosomes and Heal Full-Thickness Skin 
Defects in a Diabetic Rat Model. Stem Cells Transl 
Med. 2017;6(3):736–747.
194
I. V. Orlovska, A. H. Haidak, N. O. Kozyrovska
107. Xu N, Wang L, Guan J, Tang C, He N, Zhang W, 
Fu S. Wound healing effects of a Curcuma zedoaria 
polysaccharide with platelet-rich plasma exosomes 
assembled on chitosan/silk hydrogel sponge in a 
diabetic rat model. Int J Biol Macromol. 
2018;117:102–107.
108. Irvin J, Danchik C, Rall J, Babcock A, Pine M, 
Barnaby D, Pathakamuri J, Kuebler D. Bioactivity 
and composition of a preserved connective tissue 
matrix derived from human placental tissue. J Bio-
med Mater Res B Appl Biomater. 2018.
109. Smiell JM, Treadwell T, Hahn HD, Hermans MH. 
Real-world Experience With a Decellularized De-
hydrated Human Amniotic Membrane Allograft. 
Wounds. 2015;27(6):158–69.
110. Zelen CM, Serena TE, Fetterolf DF. Dehydrated 
human amnion/chorion membrane allografts in pa-
tients with chronic diabetic foot ulcers: A long-term 
follow-up study. Wound Med. 2014, 4:1–4.
111. Maan ZN, Rennert RC, Koob TJ, Januszyk M, 
Li WW, Gurtner GC. Cell recruitment by amnion 
chorion grafts promotes neovascularization. J Surg 
Res. 2015;193(2):953–962.
112. Park JY, Lee J, Jeong M, Min S, Kim SY, Lee H, 
Lim Y, Park HJ. Effect of Hominis Placenta on 
cutaneous wound healing in normal and diabetic 
mice. Nutr Res Pract. 2014;8(4):404–9.
113. Singh N, Bhattacharyya D. Biochemical and func-
tional analysis of corticotropin releasing factor puri-
fied from an aqueous extract of human placenta used 
as wound healer. J Pharm Biomed Anal. 
2017;145:298–306.
Сучасні технології регенеративної медицини 
у лікуванні незагоювальних шкірних ран
І. В. Орловська, І. О. Яковенко, А. Х. Гайдак, 
Д. З. Змейкоскі, Н. О. Козировська
Сучасні напрямки  регенеративної медицини, інспіро-
вані  досягненнями  у галузі клітинної біології, генної 
інженерії, синтетичної біології, матеріалознавства, 
довершують традиційну терапію, що робить можливим 
лікування хронічних недуг. У наш час  лікування хро-
нічних ран можливе через використання клітинних 
регенеративних технологій та більш пізніх неклітинних 
терапевтичних підходів. В огляді ми розглядаємо аль-
тернативні підходи до лікування незагоювальних ран 
за допомогою клінічного застосування стовбурових 
клітин, а також клітинних та тканинних продуктів. Для 
клітинних технологій регенерації тканин та біоінже-
нерії використовують стовбурові клітини, які вводять-
ся у кров›яне русло або  безпосередньо у рану. Інший 
підхід грунтується на регенераційних неклітинних 
технологіях, які потребують продуктів стовбурових 
клітин, тобто, секретомів або їхніх окремих компонен-
тів — позаклітинних мембранних везикул, а також 
тканинних продуктів. Технологія стовбурових клітин 
призначена для заміни критично відсутніх компонен-
тів пошкоджених або дегенеративних тканин. Секретом 
стовбурових клітин, незалежно від стовбурових клітин, 
може сприяти відновленню пошкоджених тканин. 
Позаклітинні мембранні везикули здатні імітувати 
механізми стовбурових клітин в процесі регенерації 
тканин і, отже, є переспективними у лікуванні хроніч-
них ран та ускладнених опіків. Тканинні продукти 
традиційно залишаються ефективними засобоми за-
гоювання ран на тлі  сучасних технологій.
К л юч ов і  с л ов а: загоєння ран, клітинні і неклі-
тинні технології, стовбурові клітини, cекретоми, поза-
клітинні мембранні везикули, тканинні продукти
Современные  технологии регенеративной 
медицины для лечения незаживающих 
кожных ран
И. В. Орловская, И. О. Яковенко, А. Х. Гайдак, 
Д. З. Змейкоски, Н. А. Козыровская
Современная терапия регенеративной медицины на-
ходится под влиянием достижений в области клеточ-
ной биологии, генной инженерии, синтетической био-
логии и материаловедения, которые совершенствуют 
традиционную терапию и делают возможным лечение 
хронических недугов. В наше время лечение незажи-
вающих ран возможно благодаря использованию ре-
генеративных клеточных технологий и более совре-
менных неклеточных терапевтических подходов. В об-
зоре рассмотрены альтернативные методы лечения 
незаживающих ран с использованием стволовых кле-
ток, а также клеточных и тканевых продуктов. Для 
клеточных технологий регенерации тканей и биоин-
195
Regenerative medicine advanced therapy for the non-healing cutaneous wound
женерии используют стволовые клетки, которые вво-
дятся в кровяное русло или непосредственно в рану. 
Другой подход основан на регенеративных неклеточ-
ных технологиях, которые используют продукты ство-
ловых клеток, то есть, секретомы или их отдельные 
компоненты — внеклеточные мембранные везикулы, 
а также тканевые продукты. Методики с использова-
нием стволовых клеток предназначены для замены 
критически отсутствующих компонентов поврежден-
ных или дегенеративных тканей. Секретомы стволовых 
клеток, независимо от стволовых клеток, могут спо-
собствовать восстановлению поврежденных тканей. 
Внеклеточные мембранные везикулы способны ими-
тировать механизмы регенерации тканей стволовыми 
клетками и, следовательно, являются перспективными 
для лечения хронических ран и осложненных ожогов. 
Тканевые продукты традиционно остаются эффектив-
ным методом заживления ран среди других современ-
ных терапевтических технологий.
К л юч е в ы е  с л ов а: заживление ран, клеточные и 
неклеточные технологии, стволовые клетки, cекрето-
мы, внеклеточные мембранные везикулы, тканевые 
продукты
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